Abstract
This study verified whether radical treatment for hepatocellular carcinoma (HCC) oligo-recurrence after liver transplantation conveys survival benefits. A retrospective study of 144 patients with posttransplant HCC recurrence was performed. Propensity score matching was performed to adjust for baseline covariates between patients who received radical and palliative treatments. The primary endpoint was postrecurrence survival. A total of 50 patients (35%) received radical treatment for recurrence, and 76 (53%) and 18 (13%) patients received palliative and supportive treatments, respectively. Compared with the radical group, patients who received palliative treatment had more early recurrences (time from transplant 17 versus 11months; P=0.01) and more extensive disease in terms of tumor numbers (1 versus 4; P<0.001), size of largest tumor (1.8 versus 2.5cm; P=0.046), numbers of involved organs (interquartile range [IQR], 1-1 versus 1-2; P=0.02), and alpha-fetoprotein (AFP) level (7 versus 40ng/mL; P=0.01). Multivariate Cox regression analysis revealed that early recurrence (time from transplant hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01-1.03; P=0.001), larger recurrent tumor (HR, 1.12; 95% CI, 1.03-1.23; P=0.01), liver recurrence (HR, 1.84; 95% CI, 1.17-2.90; P=0.01), and log10 AFP level at recurrence (HR, 1.27; 95% CI, 1.07-1.52; P=0.01) predicted poor survival. Mammalian target of rapamycin inhibitor (HR, 0.331; 95% CI, 0.213-0.548; P<0.001) and radical treatment (HR, 0.342; 95% CI, 0.213-0.548; P<0.001) were associated with improved survival. After 2-to-1 propensity score matching for covariates, the 50 patients who received curative treatment survived significantly longer than the 25 matched patients who received palliative treatment (median survival time, 30.9±2.4 versus 19.5±3.0months; P=0.01). Radical treatment conveys survival benefits to HCC oligo-recurrence after liver transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
